LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer
19-11-2018
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16-11-2018
marrio31 / iStockphoto.com
The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
LSPN Europe 2018, generics, generic litigation, market authorisation, second medical use, Novartis, Hogan Lovells, Hatch-Waxman
